InvestorsHub Logo
Followers 466
Posts 26938
Boards Moderated 2
Alias Born 09/11/2006

Re: surf1944 post# 113

Tuesday, 07/31/2012 9:31:11 AM

Tuesday, July 31, 2012 9:31:11 AM

Post# of 539
6:11AM Acorda Therapeutics reports EPS in-line, beats on revs (ACOR) 24.74 : Reports Q2 (Jun) earnings of $0.27 per share, in-line with the Capital IQ Consensus Estimate consensus of $0.27; revenues rose 15.9% year/year to $75.7 mln vs the $72.17 mln consensus. The co is reiterating 2012 AMPYRA net sales guidance of $255-$275 mln as well as FY R&D and SG&A levels. For the quarter ended June 30, 2012, the co closed with cash, cash equivalents and short-term and long-term investments of $303.0 mln, up from $295.3 mln in the first quarter.

Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.